Photofrin

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company:

QLT

Approval Status:

Approved January 1998

Specific Treatments:

Non-small cell lung cancer

Therapeutic Areas

Find Related Trials for The Following Conditions

General Information

QLT PhotoTherapeutics' light-activated drug Photofrin (porfimer sodium) was approved for injection in treating early-stage, microinvasive lung cancer. It is approved for use in patients with microinvasive endobronchial non-small cell lung cancer at an early stage, for whom surgery and radiotherapy are not indicated.